12-Hour fixed-dose combination of andrenergic agonist and cholinergic antagonist in a new administration device: analytical review

Abstract

The article presents an analytical review of the use of aclidinium, formoterol, and combination of aclidinium and formoterol to treat chronic obstructive pulmonary disease (COPD) using a metered-dose dry powder inhaler Genuair® to administer a fixeddose combination. It is noted that twelve hours’ double bronchodilating effect has some advantages including the rapid elimination of drugs having minimal systemic effects, significant effect on dyspnoea and exhalation rates, profitability of using this drug. It is proven that Genuair® is a new, patient-friendly, easy to administer at any age powder inhaler with an informative feedback mechanism. All this makes it possible to consider a new fixed-dose combination of bronchodilators in the innovative device to be a promising basic therapy for COPD.